Pediatric obstructive sleep apnea testing: in-lab PSG vs. home sleep apnea testing

In-lab polysomnography (PSG) is the diagnostic gold standard for pediatric OSA and the professional-society position, as of the sources retrieved here, is that unattended home sleep apnea testing (HSAT) is not recommended for children. This domain holds context on why PSG is nonetheless burdensome (access, wait times, tolerability), what evidence exists for pediatric HSAT specifically, and whether any device on the US market already carries a pediatric OSA indication. Expect this file to be thin on reimbursement, care pathway, and market dynamics — those sections were searched but returned little or were blocked by gated federal hosts (cms.gov, fda.gov) and a missing local CMS data cache; that thinness is stated in each section rather than papered over.

This file carries no confidence tags. Every line below is context with a source attached. To affect a score, a line must be copied into a candidate's ## Claims as unverified and pass the Verifier or Corroborator. See README.md in this directory.

1. Condition & epidemiology

as_of: 2026-08-27 · sources searched: connectors literature (pediatric obstructive sleep apnea prevalence United States, obstructive sleep apnea children epidemiology systematic review prevalence), literature-detail on PMID 22926176, 31159603 · not searched: incidence trend over time, demographic/racial concentration, US-specific state-level prevalence estimates (the sources below are national US technical-report and review-level figures, not a fresh epidemiological survey)

Verbatim, load-bearing:

"The prevalence of OSAS ranged from 0% to 5.7%, with obesity being an independent risk factor." — [1], American Academy of Pediatrics technical report, Pediatrics, 2012

"Obstructive sleep apnea in children has a prevalence of 5%." — [2], Expert Review of Medical Devices, 2019

Gaps: No US Census-scaled absolute count of children aged 5-17 with suspected or confirmed OSA was retrieved — the figures above are prevalence percentages, not converted to a population count, and doing so was not attempted this pass (that conversion is TAM work belonging to a candidate file, not this dossier). Incidence (new diagnoses per year) was not searched. Racial, socioeconomic and geographic concentration — reported elsewhere in the literature as skewing toward Black children and children with obesity — was not searched this pass; a title-only hit exists (PMID 41729304, "The influence of obesity on the risk and severity of obstructive sleep apnea in referred prepubescent children," 2026) but was not read past the title and is not carried in as a finding.

2. Care pathway & clinical setting

as_of: 2026-08-27 · sources searched: connectors literature (tonsillectomy referral delay sleep apnea children, pediatric polysomnography waiting list) · not searched: a structured description of who orders the sleep study, where PSG capacity physically sits (children's hospital vs. free-standing sleep lab), and typical channel/staffing setup for a pediatric PSG bed

Verbatim, load-bearing (non-US, flagged as such):

"Mean Wait-1 was 9.0 ± 7.0 months, Wait-2 was 6.2 ± 3.6 months, and total referral-to-surgery delay was 15.2 ± 8.6 months." — [3], International Journal of Pediatric Otorhinolaryngology, 2026, n=82 consecutive pediatric adenotonsillectomy patients, 22-month retrospective window, Canada, not US

"Diagnosis and treatment of obstructive sleep apnea (OSA) in children is often delayed due to the high prevalence and limited physician and sleep testing resources. As a result, children may be referred to multiple specialties... resulting in long waitlists." — [4], Journal of Otolaryngology - Head & Neck Surgery, 2021, n=469 US pediatric OSA clinic cohort (institution not specified in the retrieved abstract; treated here as US on the basis of author/journal context only, not independently confirmed — flag this if reused)

Gaps: No US-specific quantified PSG or adenotonsillectomy wait-time figure was located — [3] is Canadian and quantified, [4] is qualitative ("long waitlists") without a number. Nothing was found (as opposed to not searched) on a direct search for pediatric sleep laboratory access disparities wait and pediatric sleep study no-show cancellation, both of which returned zero PubMed records. Who performs PSG scoring, what technologist staffing a pediatric sleep lab bed requires, and site-of-service detail (freestanding lab vs. hospital-based) were not searched.

3. User groups & incentives

as_of: 2026-08-27 — not searched. No source has been queried for this section this pass. The shape is nonetheless visible from sections 2, 4 and 5: prescriber/decider is typically a pediatric otolaryngologist or pediatric sleep physician; operator is a sleep technologist (PSG) or a parent (HSAT, per [5]); purchaser is the sleep lab or hospital; payer and patient/family incentives are entirely unevidenced here.

Gaps: the entire section.

4. Standard of care & clinical evidence

as_of: 2026-08-27 · sources searched: connectors literature, literature-detail on PMID 28877820, 22926176, 34323688, 42165382, 42019302; WebFetch of the AASM position paper full text (PMC5612636) · not searched: the current (post-2017) AASM pediatric scoring manual text itself (licensed, human-attached per repo convention), any AASM update after 2017 specific to HSAT

Verbatim, load-bearing:

"Use of a home sleep apnea test is not recommended for the diagnosis of obstructive sleep apnea in children." — [5], AASM Position Paper, Journal of Clinical Sleep Medicine, 2017-10-15, PMID 28877820

"[The task force] was unable to identify literature on the use of HSAT devices that monitor CO2 or have the ability to identify arousals, measurements that have been viewed as critical in pediatric populations" — [5]

"The prevalence of OSAS ranged from 0% to 5.7% ... Most diagnostic screening tests had low sensitivity and specificity." — [1]

"Acceptable recordings were obtained for every home T2PSG ... Comparison of home T2PSG to T1PSG for diagnosing OSA showed a false-positive rate of 6.6% and false-negative rate of 3% for those performed at home." — [7]

Read this narrowly and in both directions, the way the candidate's own claim 11 already flags. The load-bearing guideline evidence ([5]) is dated 2017 and speaks specifically against device-type HSATs lacking CO2/arousal detection — this is not a stale-and-forgotten position, it is the standing professional-society position as retrieved by this pass, and no 2026-vintage AASM update rescinding or narrowing it was located. Set against that, the more recent systematic review [6] (2026) and the home-Type-2-PSG comparator study [7] (2022, but non-US and testing a full multichannel ambulatory PSG rig, not a limited-channel commercial HSAT device) both report favorable pediatric concordance — but [7] is a home-administered attended-equivalent PSG montage, not the limited nasal-pressure/thermistor/effort-belt/SpO2 montage this candidate proposes, and [6]'s own conclusion (per its abstract) still frames HSAT as reliable only "when used with multiple channels, including EEG and capnography" — i.e., not the channel set in idea-005's mechanism: field, which explicitly excludes EEG and CO2. This is a specific and direct tension the candidate's Factor 1 and Factor 6 narratives should read closely: the two most favorable pediatric HSAT findings located both describe devices with more channels than the one proposed.

Gaps: No post-2017 AASM position-paper update was located (not found, not merely not searched — a direct search for "AASM pediatric obstructive sleep apnea clinical practice guideline home sleep apnea test polysomnography 2023 2024" surfaced only the 2017 paper and the 2012 AAP guideline as guideline-level sources). The AASM Scoring Manual v3 pediatric scoring rules (event definitions, hypopnea criteria) are licensed and were not read in primary text. [6]'s and [7]'s full text/methods were not read past the structured abstract.

5. Reference products — and why people stop using them

as_of: 2026-08-27 · sources searched: connectors literature, literature-detail; connectors 510k, classification, clearances, clearance-summary, recalls on product code MNR; WebFetch of the AASM position paper · not searched: MAUDE narratives (no connector in this repo — docs/backlog.md 1.9), commercial-distribution status of any device below, adult HSAT device pricing

In-lab polysomnography (PSG) — the incumbent standard, not a competing device

• What it is / cleared indication: Attended, technologist-supervised, multi-channel (EEG, EOG, EMG, ECG, airflow, respiratory effort, SpO2) overnight recording in a sleep laboratory. Not itself a single cleared device; the diagnostic modality against which every HSAT is validated.
• Evidence behind it: [1] — reference standard by professional-society consensus, per the 2012 AAP technical report reviewing 3,166 titles.
• Adoption: Not established as a utilization number in this pass; established qualitatively as the default/required pathway per [5].
• Abandonment record — why people stop (access/tolerability, not efficacy):

• Verbatim, load-bearing:

"Traditional in-laboratory level 1 polysomnography remains the gold standard to diagnose paediatric sleep-disordered breathing (SDB) and obstructive sleep apnoea (OSA). However, in-laboratory tests present significant barriers, including long waitlists, limited accessibility, particularly for rural/remote families and burdensome hospital stays." — [8], Sleep Medicine, 2026

"Mean Wait-1 was 9.0 ± 7.0 months... total referral-to-surgery delay was 15.2 ± 8.6 months." — [3]

Read this carefully. No US-specific quantified PSG wait-time, no-show, or cancellation rate was located — the direct queries for "no-show," "cancellation" and "access disparities" each returned zero PubMed records, and this is recorded as not found, not merely not searched. The one quantified wait-time figure on record ([3]) is Canadian; the one US-context source ([4]) is qualitative only. This is the load-bearing gap in the file: the candidate's whole demand premise (families/clinicians circumventing PSG's burden) currently rests on a qualitative statement from a 2026 review plus a non-US quantified proxy, not on a US cohort study of PSG abandonment, no-show, or dropout.

Home sleep apnea test (HSAT) devices with any pediatric clearance or validation

• SNAP Diagnostics SAM Model 9-10000 (K240100) — Class II, product code MNR ("Ventilatory Effort Recorder"), 21 CFR 868.2375 per the classification database (note the discrepancy below), decided 2024-06-04. Verified this pass: `510k "SAM" --applicant "SNAP Diagnostics" and classification --device-name "ventilatory effort recorder"` both confirm the record and product code independently of the candidate file's own prior research. Its Indications for Use are recorded by the candidate's own Verifier pass as reading, verbatim, "Both pediatric and adult patients may be tested" — **this dossier did not re-open the 510(k) summary PDF itself** (this environment's clearance-summary tool returned unconfirmed: "pypdf is not installed, so 510(k) summary PDFs cannot be read"), so that specific quote is carried here as a pointer to the candidate file's finding, not as independently re-verified by this dossier pass.
  • Regulatory-text discrepancy, worth flagging structurally: `connectors regulation 868.2375` returns the CFR text for "Breathing frequency monitor" (a respiratory-rate alarm device), which does not contain the phrase "ventilatory effort recorder" — openFDA's device/classification record names regulation 868.2375 for product code MNR, but the eCFR text at that section number describes a different device type. This is the same class of classification-database-vs-eCFR mismatch already documented in this repo's potassium-monitoring-ckd dossier for a different product code (870.2380) — flagged here so a later reader does not treat "21 CFR 868.2375" as confirmed, on-point CFR text.
• WatchPAT family (Itamar Medical / ZOLL) — Verified this pass: `510k "WatchPAT" --applicant "Itamar"` confirms WatchPAT ONE (K223675), decided 2023-01-06, product code MNR. Per the candidate file's prior Verifier pass (not independently re-opened here for the age-range language, same pypdf limitation), the family is cleared "for 12 years and older" for most parameters.
• ApneaLink Air (ResMed) — Adult-cleared HSAT device (per its own trial's summary: "The ApneaLink Air HST device is cleared for the diagnosis of obstructive sleep apnea (OSA) in adults"), being separately validated in adolescents by ResMed itself — see the trial below. No pediatric clearance located for this device by this pass.
• AASM's own 2017 negative finding, restated as reference-product evidence: "the task force was unable to identify literature on the use of HSAT devices that monitor CO2 or have the ability to identify arousals" — i.e., as of 2017 the professional society itself could not identify a pediatric-validated HSAT device meeting what it considered necessary measurement criteria. — [5]
• **Registered validation studies (Stage-0 scan facts, no confidence tag possible per connectors/result.py — recorded here as pointers, not findings):**
  • NCT03748771, "Validation of ApneaLink Air Home Sleep Testing in the Diagnosis of Obstructive Sleep Apnea in Adolescent Children" — COMPLETED, sponsor ResMed (INDUSTRY), enrollment 20 (ACTUAL), ages 12-17, primary outcome "Accuracy of HST Compared to ALT (ApneaLink Lab Testing) and PSG," secondary outcomes include "Patient Satisfaction" and "Number of Successful HST Evaluations." **hasResults=true, but this dossier could not retrieve the posted numeric results** — a WebFetch of the results tab returned only page navigation content, no data. Recorded as not retrieved, not as a finding either way.
  • NCT05382754, "Home Apnea Testing in CHildren Trial" — RECRUITING, sponsor Children's Hospital of Philadelphia, enrollment 317 (ESTIMATED, a target, not a completed count), ages 5-12, primary outcome "Proportion of participants with diagnosis of OSA on both HSAT and PSG," secondary outcomes include "Proportion of participants who prefer HSAT to PSG" (registered but unposted — this is the closest a registry gets to the class-3 preference question, and it has not reported).

Gaps: No pediatric-specific HSAT device pricing was located. No MAUDE complaint or failure-mode data exists for any device named here (no connector reaches MAUDE — repo-level gap, docs/backlog.md 1.9). One recall exists in the MNR product code in the last six years — Z-0031-2022 (Nox Medical, Nox T3s Recorder, terminated, "Error in the device firmware results in the inaccurate detection of device position," related to K082113) — not specific to pediatric use and not tied to either K240100 or the WatchPAT family, recorded here as the one enforcement signal found in this product code's recent history.

6. Reimbursement landscape

as_of: 2026-08-27 · sources searched: connectors hcpcs, coverage (on placeholder codes G0399); WebSearch for HCPCS G-code descriptions; WebFetch attempt of a CMS LCD page · not searched: any state Medicaid sleep-testing policy, any named commercial payer policy

Not established from a primary source. data/ holds no CMS HCPCS or coverage-policy cache (confirmed this pass: ls data/ shows only README.md), so hcpcs and coverage both return unconfirmed — "No local cache at data/hcpcs_level_ii.csv / data/medicare_coverage_policies.csv." Per repo convention, this null is a missing-file condition, not evidence that no code exists.

A WebSearch surfaced three HCPCS Level II G-codes commonly cited for unattended home sleep testing — G0398 (Type II, ≥7 channels including EEG), G0399 (Type III, ≥4 channels), G0400 (Type IV, ≥3 channels) — but every source located was a coding-vendor page (AAPC), not a CMS-hosted primary document, and a WebFetch of the CMS Medicare Coverage Database LCD page (L36861) returned HTTP 403. Per the rule that a search result is never a source of record, these three code numbers are recorded here as an unverified lead, not as an established finding — a later pass with a working HCPCS cache or a successful CMS fetch should independently confirm the code numbers, descriptors, and whether any age restriction attaches to them, before they are used in any candidate claim.

CPT descriptors (95800/95801/95806 for HSAT, 95782/95783 for attended pediatric PSG under age 6) are AMA-licensed and are not reproduced here; the candidate file's own Claims record these as permanently unconfirmed absent a human-attached licensed source, consistent with this repo's standing rule.

Gaps: the entire section beyond the unverified G-code lead above. No coverage-policy document (Medicare NCD/LCD, commercial, or Medicaid) was successfully retrieved. Whose budget an outpatient pediatric sleep referral draws from, and any site-of-service differential between a freestanding sleep lab and a hospital-based one, were not searched.

7. Technology trajectory

as_of: 2026-08-27 — not searched this pass beyond what section 5 already surfaced (the MNR product-code clearance sweep). What has changed in sensor miniaturization, pediatric cuff/belt sizing, or signal-processing approaches to scoring pediatric-specific event definitions over the last decade was not searched. Note the repo-wide constraint that a counted series (clearances per year in product code MNR) cannot itself carry a confidence tag and is not restated here beyond what section 5 already used it for.

Gaps: the entire section.

8. Market players & dynamics

as_of: 2026-08-27 · sources searched: the MNR-product-code clearances/recalls sweep already run for section 5 · not searched: funding, launches, or exits specific to pediatric HSAT as a market segment (as opposed to the regulatory clearance roster)

Gaps: No funding, launch-announcement, or company-exit data specific to a pediatric HSAT market segment was searched. This table is derived entirely from the regulatory clearance and recall sweep already run in §5, not from an independent market-players search.

9. Open questions — and what would settle them

Class-3 questions above are recorded, never answered, and paired with their nearest revealed-behaviour twin per docs/research-lane-spec.md §3.1.

10. Provenance & staleness

What this dossier has never looked at: care pathway staffing and site-of-service detail (§2/§3 in full); any reimbursement primary source beyond an unverified secondary-source HCPCS lead (§6); technology trajectory and market dynamics beyond what a single regulatory clearance sweep incidentally surfaced (§7/§8); MAUDE device-complaint data (no connector exists in this repo for it); the licensed AASM pediatric scoring manual and any FDA guidance document (both gated per standing repo constraints — fda.gov gates intermittently, the scoring manual is licensed); and any US-specific quantified PSG wait-time, no-show or cancellation figure, which was searched for directly and not found, as distinct from the rest of this list, which was largely not searched. A later pass with a working pypdf installation, a populated data/ CMS cache, and a successful CMS/fda.gov fetch would close several of the largest gaps here without needing new literature.

Sources

1. PMID 22926176 — Marcus CL et al., "Diagnosis and management of childhood obstructive sleep apnea syndrome" (technical report), Pediatrics, 2012.
2. PMID 31159603 — "Towards Patient-centered Diagnosis of Pediatric Obstructive Sleep Apnea-A Review of Biomedical Engineering Strategies," Expert Review of Medical Devices, 2019.
3. PMID 42480311 — "Reducing referral-to-consultation delays in pediatric obstructive sleep apnea through standardized triage: A regional quality improvement initiative," International Journal of Pediatric Otorhinolaryngology, 2026 (Bas-Saint-Laurent, Québec, Canada — non-US).
4. PMID 34266488 — "Development of a pediatric obstructive sleep apnea triage algorithm," Journal of Otolaryngology - Head & Neck Surgery, 2021.
5. PMID 28877820 — "American Academy of Sleep Medicine Position Paper for the Use of a Home Sleep Apnea Test for the Diagnosis of OSA in Children," *Journal of Clinical Sleep Medicine*, 2017-10-15; full text via PMC5612636 (https://pmc.ncbi.nlm.nih.gov/articles/PMC5612636/).
6. PMID 42165382 — "Reliability of Home Sleep Apnea Test as a Diagnostic Modality in Children With Obstructive Sleep Apnea- a Systematic Review," Pediatric Pulmonology, 2026.
7. PMID 34323688 — Withers A, Maul J, Rosenheim E, O'Donnell A, Wilson A, Stick S, "Comparison of home ambulatory type 2 polysomnography with a portable monitoring device and in-laboratory type 1 polysomnography for the diagnosis of obstructive sleep apnea in children," Journal of Clinical Sleep Medicine, 2022;18(2):393-402 (Australia — non-US).
8. PMID 42019302 — "Sweet dreams at home: A review of paediatric domiciliary sleep studies," Sleep Medicine, 2026.
9. openFDA device/510k, k_number=K240100 — SAM Model 9-10000, Snap Diagnostics, LLC, decided 2024-06-04 (verified via python3 -m connectors 510k "SAM" --applicant "SNAP Diagnostics").
10. openFDA device/classification, product_code=MNR — "Ventilatory Effort Recorder," Class II, regulation 868.2375, review panel AN (verified via `python3 -m connectors classification --device-name "ventilatory effort recorder"`).
11. openFDA device/510k, k_number=K223675 — WatchPAT ONE (WP1), Itamar Medical, Ltd., decided 2023-01-06 (verified via python3 -m connectors 510k "WatchPAT" --applicant "Itamar").
12. eCFR versioner, title 21, issue 2026-08-19, section 868.2375 ("Breathing frequency monitor") — retrieved via `python3 -m connectors regulation 868.2375 --expect "ventilatory effort recorder"; returned unconfirmed` (text does not contain the expected phrase).
13. ClinicalTrials.gov NCTId=NCT03748771 — "Validation of ApneaLink Air Home Sleep Testing in the Diagnosis of Obstructive Sleep Apnea in Adolescent Children," sponsor ResMed, status COMPLETED, hasResults=true (posted results not retrieved this pass).
14. ClinicalTrials.gov NCTId=NCT05382754 — "Home Apnea Testing in CHildren Trial," sponsor Children's Hospital of Philadelphia, status RECRUITING, hasResults=false.
15. openFDA device/recall, product_res_number=Z-0031-2022 — Nox Medical, Nox T3s Recorder, status Terminated, initiated 2021-09-07, related 510(k) K082113.
16. Secondary source, not independently verified against a primary CMS document (recorded per §6's disclosure rule, not as an established finding): AAPC coding-reference pages for HCPCS G0398, G0399, G0400 (https://www.aapc.com/codes/hcpcs-codes/G0398, /G0399, /G0400).
17. CMS Medicare Coverage Database, LCD L36861 ("Polysomnography and Other Sleep Studies") — attempted via WebFetch, returned HTTP 403; not retrieved.